Form 8-K - Current report:
SEC Accession No. 0000950170-25-071382
Filing Date
2025-05-14
Accepted
2025-05-14 16:09:24
Documents
15
Period of Report
2025-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tennx-20250514.htm   iXBRL 8-K 59872
2 EX-99.1 tennx-ex99_1.htm EX-99.1 22740
3 GRAPHIC img152374366_0.jpg GRAPHIC 87390
4 GRAPHIC img152374366_1.jpg GRAPHIC 188650
5 GRAPHIC img152374366_2.jpg GRAPHIC 388509
  Complete submission text file 0000950170-25-071382.txt   1192726

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tennx-20250514.xsd EX-101.SCH 26341
17 EXTRACTED XBRL INSTANCE DOCUMENT tennx-20250514_htm.xml XML 4716
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34600 | Film No.: 25945515
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)